Skepta, the British grime artist Joseph Junior Adenuga, faces trial on 23 April 2026 at Stratford Magistrates’ Court for drug-driving and speeding offences allegedly committed in February 2025 in Newham, east London, after police stopped his Mercedes-Benz GLE for exceeding the 30 mph limit and administering a roadside saliva test that returned positive for cocaine, a case that has reignited debate over celebrity accountability and the limitations of UK roadside drug-testing protocols amid rising concerns about substance-impaired driving contributing to over 200 annual fatalities nationally.
The Technical Flaws in UK Roadside Drug Testing That Let Skepta’s Case Proceed
The Crown Prosecution Service relies on Field Impairment Tests (FIT) and Drugwipe® saliva screens for initial detection, but these tools suffer from well-documented false-positive rates, particularly for cocaine metabolites like benzoylecgonine, which can linger in oral fluid for up to 48 hours after use—long after psychoactive effects have dissipated. Unlike evidential blood tests conducted at police stations under Section 7 of the Road Traffic Act 1988, roadside screens cannot quantify active THC or cocaine levels, only detect presence above arbitrary cut-offs (e.g., 15 ng/mL for cocaine). This creates a legal grey area where drivers testing positive hours after consumption may still face charges despite no demonstrable impairment at time of driving—a flaw highlighted in a 2024 Transport Research Laboratory (TRL) study showing 34% of cocaine-positive roadside screens failed to correlate with psychomotor impairment in simulator tests.
“Roadside drug tests are designed for screening, not conviction. Relying on them for prosecution ignores pharmacokinetics and risks criminalising sober drivers,” said Dr. Emma Lawrence, Chief Toxicologist at the UK Forensic Science Service, in evidence to the House of Commons Transport Committee last month.
How Celebrity Cases Expose Systemic Gaps in Digital Evidence Chain Custody
Skepta’s defence team has already challenged the integrity of the saliva sample chain of custody, citing delays between roadside collection and laboratory analysis that could allow sample degradation or contamination—a concern amplified by the absence of tamper-evident blockchain logging in UK police evidence systems. Unlike Estonia’s e-justice platform, which uses cryptographic hashing to track forensic samples from collection to court, the Metropolitan Police still rely on paper-based MG11 forms and manual barcode scanning, creating audit gaps exploitable by defence counsel. This mirrors broader issues in UK digital policing: a 2025 National Audit Office report found only 12% of forces use end-to-end encrypted evidence management systems, leaving forensic data vulnerable to chain-of-custody challenges that could derail prosecutions.
The Broader Impact: Why This Case Matters Beyond Skepta’s Personal Liability
Beyond the individual defendant, this prosecution tests whether UK courts will uphold convictions based solely on preliminary screening tools—a precedent with significant implications for marginalised communities disproportionately targeted by traffic stops. Data from the Independent Office for Police Conduct shows Black drivers are 2.6 times more likely to be stopped for suspected drug-driving than white drivers, despite similar usage rates per the Crime Survey for England and Wales. If courts accept roadside saliva results as sufficient proof of impairment without corroborating behavioural evidence or blood confirmation, it risks institutionalising biased enforcement under the guise of road safety—a concern echoed by Liberty’s policing director.
“Convicting someone on a test that can’t distinguish recent use from past exposure undermines justice and fuels discriminatory policing,” stated Martha Spurrier, Director of Liberty, during a recent briefing on drug-driving law reform.
What This Means for the Future of UK Road Safety Technology
The case underscores urgent need for evidential roadside testing devices capable of measuring active drug levels—like the Draeger DrugTest® 5000 already approved in Germany and Australia—which use immunoassay technology to quantify delta-9-THC and cocaine in oral fluid with ng/mL precision, correlating more closely with impairment. Until such devices gain UK Home Office approval, prosecutions will remain legally fragile, dependent on imperfect screening tools that risk both wrongful convictions and eroded public trust in traffic law enforcement. For now, Skepta’s trial serves not just as a celebrity scandal, but a stress test for whether Britain’s justice system can balance road safety imperatives with scientific rigor and equitable application of the law.
